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Abstract
Depending on the tumour type, a larger or smaller
number of cancer patients receive chemotherapy with
systemic toxicity as the only effect. In that situation, an
alternative, not necessarily medical, treatment would
have been a better choice – and toxicity (and ﬁnancial
resources) could have been spared by withholding
ineffective drugs. One of the reasons for this apparent
paradigm is that the tumour cells of each cancer pa-
tient may show different sensitivity/resistance towards
different chemotherapeutic drugs, i.e. breast cancer
or colorectal cancer is not only breast or colorectal
cancer. With our increasing biological insight and
understanding, it has become apparent that each
patient’s tumour tissue is unique and as a consequence,
each patient’s tumour cell sensitivity/resistance to-
wards chemotherapeutic drugs may be different. As
of today there is no method in routine clinical use
to predict the sensitivity/resistance to chemotherapy in
its broad sense in the individual patient. This chapter
will describe several different DNA, RNA, protein and
cell based assay methodologies and marker molecules
that have been brought forward as potential predictive
assays/markers to be used to select the most effective
drugs for the individual cancer patient.
Introduction
Despite the continuous development of new cancer
treatment strategies, including optimisation of already
known drugs, as well as development of new targeted
therapies, too many cancer patients still experience
recurrence of their disease with subsequent disease
related death. It is thus clear that in order to lower
the number of deaths, there is an urgent need for
the development of more effective treatment strategies
including the introduction of new procedures for
optimal prediction of response to treatment. Anti-
cancer drug treatment given either alone or in various
combinations includes different types of chemotherapy
(cytotoxic drugs), endocrine therapy, immunotherapy
and recently speciﬁed targeted therapies. In most
metastatic cancer diseases, the objective response rates
(complete and partial responses) to any of these
treatment options are far from 100%. This means
that a signiﬁcant number of cancer patients receive
chemotherapy with no other effect than systemic
toxicity.
While detection of oestrogen and progesterone
receptors in breast cancer is a well established routine
method to predict objective response to endocrine
therapy, there is at present no accepted method to
determine whether a cancer patient will beneﬁt from
chemotherapy in its broad sense. If such a method
existed, it would allow for a tailor-made approach
resulting in individualised treatment. This would also
imply that for those patients having resistant tumours,
such an approach would not only spare them from side
effects induced by ineffective chemotherapy, but would
also have a major impact on the economics of the
health care system in terms of savings of expenses re-
lated to otherwise ineffective treatment. Furthermore,
it is now clear that predictive molecular assays must be
devised before the initiation of clinical trials for new
targeted anticancer agents. Use of predictive markers
will increase the speciﬁcity and usefulness of these
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drugs and provide a meaningful clinical evaluation
in the population of patients most likely to beneﬁt
from the treatment. Thus, the ﬁeld of cancer drug
discovery clearly needs to turn greater attention to the
problem of identifying responsive/resistant subsets of
patients early in the development process and needs
to utilise the knowledge obtained through molecular
and cellular studies of cancer biology. The present
review will focus on techniques used for identiﬁcation
and determination of predictive biomarkers and will
give examples of biomarkers used for selecting cancer
treatment to the individual patient. Instead of a
lengthy review including all potential markers, this
paper will rather give a short introduction to the
methodologies that can be used to identify new
markers for therapeutic efﬁcacy, followed by selected
examples of biomarkers that either already have
reached clinical usefulness or are in clinical testing.
At the end of the review, we will give our suggestions
for clinical validation and implementation of new
promising predictive biomarkers in the treatment of
cancer patients.
DNA biomarkers
At the cellular level cancer is a genetic disease
and the tumour cells have acquired genetic changes
that are responsible for the multistep process that
drives the malignant transformation [1]. The can-
cer speciﬁc genetic changes may lead to altered
mRNA and protein levels and may represent the
most important mechanism by which the tumour can
permanently acquire new functionality. The acquired
speciﬁc genetic changes in the cancer cells will,
however, not be present in the non-malignant cells
of the patient. Therefore, it is obvious to exploit
the speciﬁc genetic changes of the tumour cells as
diagnostic, prognostic and especially predictive tools
in the management of cancer patients. The malignant
transformation is driven by inactivation of tumour
suppressor genes combined with activation of proto-
oncogenes. The inactivation of tumour suppressor
genes can occur by a variety of mechanisms, including
physical deletion, point mutation and/or methylation –
all leading to loss of function. Proto-oncogenes, on
the other hand, can be activated by ampliﬁcation,
point mutation or structural rearrangements (Fig. 1).
Minor changes include point mutations and smaller
intragenic deletions and duplications and the DNA
amount involved ranges from a single base pair to
several millions of base pairs. These changes can be
studied by sequencing, LOH (loss of heterozygosity)
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Fig. 1. Schematic presentation of the DNA base pair scale (arbitrary
units) in relation to the technique discussed.
allelic imbalances (AI) and/or PCR based techniques
combined with blotting techniques. The methods are
precise for the detection of point mutations, but larger
deletions and duplications are not revealed. Only by
comparing the DNA sequence of the cancer cells
with the normal cells of the patient, is it possible
to distinguish point mutations from single nucleotide
polymorphisms (SNPs). Polymorphism is a normal
genetic variation present in the population and thus
not directly linked to the cancer. Further, the gene
function may be inﬂuenced by epigenetic factors, e.g.
methylation.
The major genetic changes include large stretches
of DNA, from several thousands to millions of
base pairs, and may, depending on methodology, be
detected as structural rearrangements or copy number
changes (CNC). The techniques described above for
detection of minor genetic changes cannot reveal the
major genetic changes and vice versa (Fig. 1). The
major genetic changes can be studied by CGH (com-
parative genomic hybridisation), array-CGH and/or
FISH (ﬂuorescence in situ hybridization). Using FISH
technique, structural rearrangements can be detected
as chromosome translocations and the copy number
changes are seen as ampliﬁcations, deletions, and
duplications. FISH methods for detection of these
chromosome aberrations were initially developed for
cytogenetic specimens (Fig. 2) but have later been
reﬁned to cut sections of parafﬁn embedded tissue
(Fig. 3).
The FISH technique comprises hybridising ﬂuores-
cent labelled probes with target DNA of the cancer
tissue. The gene directed probe is preferentially 200–
400 kilobase pairs in length and includes the cancer
related gene and ﬂanking regions. When selecting
the genomic clones for diagnostic use, the gene of
interest should be located at a position that excludes
or minimises presence of ﬂanking genes that could
potentially be related to cancer.
Gene copy number changes can be viewed in the
nuclei of a tissue and counted directly. A normal cell
will contain two gene copies and a deviation from this
number is indicative of an abnormal cell. However,
due to the fact that cut sections of tissue are 4−6mm
Biomarkers for therapeutic efﬁcacy 131
Chromosome 17
TOP2A - 17q21.3
Cen-17 α-satellite
Fig. 2. Localisation of TOP2A gene probe in red and centromere 17
reference probe in green schematically on an ideogram (left) and
on metaphase spread from normal human blood.
Fig. 3. TOP2A gene probe in red and centromere 17 reference
probe in green hybridised to breast cancer tissue (left) showing
ampliﬁcation and deletion (middle) and to a metaphase spread of a
cell line showing the distribution of the ampliﬁed signals onto many
different chromosomes.
in thickness and the nuclei of a cancer cell is often
10mm, this simple relationship is not applicable for
cut sections. Therefore, a reference probe is added to
the probe mix and the ratio between the gene probe
(labelled in red) and the reference probe (labelled
in green) is scored. Inclusion of a reference probe
has the further advantage that gene copy number
changes due to polyploidisation of the whole genome
can be distinguished from ampliﬁcations and allows
also the detection of deletions. As reference probe,
compensating for the ploidy level of the tumour, the
centromere of the chromosome that the gene of interest
resides on is often used, although it could be any other
region of the genome.
The FISH technique comprises of a few steps
(Fig. 4): Pretreatment for making the tissue accessible
for the probe, denaturation of probe and target by
heating in formamide buffer, overnight hybridisation,
stringent wash for removal of unbound probe, and
counterstaining and mounting. Speciﬁc details and
variations of the method are detailed by Nielsen
Step 1: Specimen Pretreatment
Step 2: Hybridisation and Stringent Wash
Step 3: Mounting and Interpretation
Fig. 4. Short outline of the FISH (ﬂuorescence in situ hybridisation)
method.
and colleagues [2]. The signals are scored using a
ﬂuorescence microscope equipped with ﬁlters that are
suited for the red and green ﬂuorochromes. A total
of 60 nuclei are normally scored, although alternative
counting methods can be used [3].
Predictive DNA biomarkers can be found by
screening cancer cell lines for ampliﬁed genes (e.g.
HER2), by studying the gene that is the target for the
drug (e.g. TOP2A) or by studying genes involved in
the pathway of the drug (e.g. EGFR). A number of
examples are described below. One of the most well-
established biomarkers is the HER2 used for selection
of patients for treatment with antibodies directed
against HER2. Initially, HER2 (alias of ERBB2) gene
ampliﬁcations were studied using Southern blotting
technique [4], followed by additional information on
the mRNA and protein level [5], eventually leading
to the development of a treatment targeting the
product of the genetic disorder of the tumour [6].
Because the HER2 protein is the therapeutic target,
much debate has been devoted to the question about
the best use of the different methods, and it is
now generally agreed upon [7] that both FISH or
IHC (immunohistochemistry) may be used for the
assessment of HER2 status in breast cancer. HER2
may, however, be an exceptional case with a very high
correlation between the gene copy number studied
by FISH and the protein immunoreactivity studied by
IHC and precaution should be taken in generalisation
from the HER2 case. Very close to the HER2 gene
on chromosome 17 is located the TOP2A gene. The
gene codes for topoisomerase IIa which is the target
for the group of widely used chemotherapeutic drugs,
the anthracyclines. The link between the biomarker
and the drug was ﬁrst described in an in vitro grown
cancer cell line [8] having ampliﬁcation of the TOP2A
gene and overexpression of the protein, and initially
it was reported that the gene copy number and the
mRNA and protein level correlated in this lung cancer
cell line [9]. Later, studies including samples from
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Fig. 5. Relative effect of Cyclophosphamide, Epirobricin and 5-FU (CEF) in each TOP2A and HER2 subgroup on recurrence free survival
(RFS) (Forrest plot). For the primary study endpoint (RFS) in the analyses using the Cox proportional hazard model showed a signiﬁcant
predictive value of TOP2A gene aberrations (P = 0.016). The group of patients with TOP2A ampliﬁcations had a relative risk reduction of
more than 60% when treated with CEF compared to CMF (M = Methotrexate) (HR= 0.389, P = 0.0017). Also for the TOP2A deletions a
risk reduction was found, however not statistically signiﬁcant (HR= 0.608, P = 0.0828).
breast cancer patients have shown that TOP2A gene
aberrations are predictive for the outcome of treatment
with anthracyclines [10,11] (Fig. 5); however, a direct
correlation between gene copy number and protein
amount has not been established [12,13]. In contrast
to HER2, the DNA and protein measurements are thus
not interchangeable in the case of TOP2A and anthra-
cyclines. This relationship is further complicated by
the existence of TOP2A deletions.
The epidermal growth factor receptor (EGFR) is
ampliﬁed or overexpressed in many cancers, including
non-small-cell lung cancer and colorectal cancer,
and is targeted by EGFR inhibitors. Much effort
has been devoted to ﬁnding a biomarker that can
be used to predict the outcome of treatment with
EGFR inhibitors. Initially, IHC, assessing the EGFR
protein, was used as a diagnostic tool, and then EGFR
mutations were reported, and eventually gene copy
number changes were described. Among the various
tests developed to predict objective response to EGFR
inhibitors, the EGFR FISH test seems to be the most
promising [14]; however, only very few studies have
included and compared all three methods [15] and
a consensus has not yet been reached regarding the
use of biomarkers for selection of therapy with EGFR
inhibitors. The consensus is also hampered by the
fact that different drugs and different cancer types
are being studied using different biomarkers (protein,
point mutation or major genetic change), different
methodologies for the biomarker and even different
cut-offs in deﬁning the discrimination between normal
(negative) and abnormal (positive) cases.
The lesson learned from the EGFR puzzle must
be that future studies of biomarkers for targeted
drugs should be well designed and include pilot
studies to determine the methodology and cut-off
levels to be used in the conﬁrmatory clinical studies.
In addition, if the pilot studies cannot point to the
right biomarker, both protein and DNA measurements
should be included in the relevant clinical trials.
Also, it is important to know that point mutations
and ampliﬁcations, although both being alterations
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Fig. 6. Schematic ﬂowchart for generating gene expression proﬁling on clinical specimen.
of the DNA, may not provide the same biological
information. Eventually, it may be a combination
of two or more techniques that should be used to
determine the biomarker status.
RNA biomarkers
Genetic mutations, genomic losses, ampliﬁcations and
epigenetic changes including those that control success
or failure of chemotherapy, are the driving forces in
cancer. The ﬁrst and currently most easily accessible
reporters of these genetic and epigenetic alterations are
the downstream transcripts that are under their control.
At present, the most commonly used methodology
to study expression of multiple genes in cancer
tissue is gene expression microarrays. At the turn
of the century the development and use of these
gene expression microarrays was greatly accelerated
with the completion of the code for the human
genome, the development of nanotechnology (i.e.
miniature robotics and high precision scanners) and
the generation of various data analysis tools to allow
processing of the multidimensional data generated.
Current gene expression arrays contain on a single
array multiple detection probes to all annotated mRNA
species of the human genome (>25K mRNA species).
Successful gene expression analysis on microarrays
and subsequent identiﬁcation of predictors of disease
states involves various steps. First, the tumour sample
has to be prepared for analysis on the microarray
(Fig. 6; top panel). Therefore, various consecutive
tissue sections have to be prepared. Using adjacent
HE stained sections, tissue predominantly containing
tumour material is selected and from these selected
sections ribonucleic acid molecules are extracted. In
general, fresh-frozen tumour material is used for gene
expression analysis since high quality RNA is needed
for this to be successful. However, today, it is also
possible to extract RNA from formalin-ﬁxed parafﬁn
embedded material. It should be mentioned, however,
that this RNA is fragmented and partially chemically
modiﬁed and therefore currently less useful for mi-
croarray discovery studies. This material is, however,
highly suited for validations of gene signatures using
e.g. quantitative RT-PCR analysis of selected genes.
After RNA extraction, the RNA is quantiﬁed and
checked for integrity by monitoring the presence of the
ribosomal 18S and 28S RNA species and the absence
of RNA degradation products. After that, RNA of
sufﬁcient quality is reverse transcribed to DNA (called
copy DNA or in short cDNA) which subsequently is
copied to double stranded cDNA. After one round of
linear ampliﬁcation, the nucleic acids representing the
original RNA composition is ﬂuorescently labelled.
Successful labelling is veriﬁed by measuring the
labelling intensity of the ampliﬁed material. At this
moment the labelled material can be applied to the
actual microarray to allow for hybridisation (Fig. 6;
middle panel). Inside the hedged box, hybridisation for
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one probe set is visualised. A probe set contains DNA
detection probes of one oligonucleotide sequence of 20
to 70 base pairs in length complementary to the gene
of interest. Since each gene is represented by multiple
probe sets to avoid non-speciﬁc detection, a complete
array contains over a 100,000 probe sets to measure
expression of all genes in the human genome. During
hybridization, labelled RNA of a sample is deposited
on a probe set only if it is complementary to the probe
sequence. At the end of the hybridisation time using a
high-resolution scanner, signal intensities for all probe
sets are measured allowing the gene expression levels
for each gene in a sample to be calculated. A typical
microarray experiment generally involves dozens of
tumour samples yielding gene expression data for all
these samples at the end of the wet part of a study for
data analysis (Fig. 6; bottom panel). Various statistical
tools are currently available to identify genes that are
at the mRNA expression level associated with the
clinical endpoint of interest. For predictive markers
the endpoints can be groups (patients who relapsed
or not or patients who did or did not respond to a
particular treatment) or time dependent measures (time
to relapse and time to therapy failure). To identify
genes that are differentially expressed between groups,
e.g. responders and non-responders, a parametric t-
test or equivalent is often used. However, due to
the high dimensionality of gene expression data a
correction to limit false discoveries is advised [16,17].
To predict classes, multi-gene predictors are developed
from the list of differentially expressed genes. For
time dependent measures, Cox regression and multi-
variate Cox models or equivalent are used for gene
selection and endpoint prediction, respectively [18].
Apart from these down-to-earth outcome predictors,
mathematically more complex algorithms such as
principle component analysis [19], support vector
machines [20], artiﬁcial neural networks [21] can also
be used to build a classiﬁer. Finally, a predictor is
usually optimised for sensitivity or speciﬁcity depend-
ing on the clinical question and its performance is
judged using leave-one-out cross validation. However,
to truly test the performance of a predictor the use of
independent cohort(s), set aside upfront or evaluated
later on, has been proven to be essential. Finally, the
results of a particular analysis are often visualised
by hierarchical clustering [22] using the identiﬁed
differentially expressed genes or using the selected set
of prognostic or predictive genes. With regard to the
clinical signiﬁcance of gene expression proﬁling, the
breakthrough came from the Stanford Laboratory who
identiﬁed, based on global gene expression, ﬁve major
subgroups in clinical breast cancer specimen [23].
Thus, within both the ER-positive (i.e. luminal A
and B) and negative (i.e. basal and normal-like)
breast cancers, at least two biologically quite distinct
subgroups are present that are different with regards to
aggressiveness [24,25] and response to neo-adjuvant
paclitaxel containing chemotherapy [26]. After these
ﬁrst landmark observations, the ﬁeld has rapidly pro-
gressed and gene signatures associated with endocrine
therapy resistance [27], and chemotherapy response
(Martens and colleagues, in preparation) [28−30]
have been revealed and predictors of bone and lung
relapse uncovered [31−33]. For clinical use, the
most promising assays are gene expression signatures
predicting disease recurrence in breast cancer patients
with lymph-node negative disease. Starting with the
70-gene signature predicting disease outcome in young
patients [34,35], a wound-healing signature [36], a
Nottingham Prognostic Index [37] and genomic grade
signature [38] predicting disease recurrence have all
been identiﬁed. A robust 76-gene signature was devel-
oped for the prediction of distant metastasis in lymph-
node negative patients irrespective of age and hormone
receptor status [39]. In addition to this, in patients
with lymph node-negative and oestrogen receptor-
positive disease receiving adjuvant endocrine therapy
with tamoxifen, a 21-gene recurrence score [40] and
a 2-gene signature, the IL17BR-HOXB13 ratio [41]
predicting disease recurrence have been identiﬁed. Of
these signatures some have been validated [42,43] but
only the 70-gene signature from Amsterdam and the
76-gene signature from Rotterdam have been validated
in large independent multi-centric cohorts [44−46].
This has allowed the initiation of prospective evalu-
ation of the performance of selected prognostic gene
signatures in Europe and in the US. Furthermore,
for a speciﬁc validated multi-gene classiﬁer the FDA
recently approved the technology to be used as a
prognostic tool in the clinic.
In conclusion, various predictive gene signatures
have been identiﬁed while others are being developed.
Even though most of them still need independent
validation, it seems no dispute that predictive gene
signatures are likely to be used for therapy decisions
in the future.
Protein biomarkers
‘Proteomics’ is a rapidly developing area of can-
cer research which promises to have an enormous
impact on prediction of therapy response in the
individual patient. Gel-based and high throughput
proteomic technologies, including two-dimensional
gel electrophoresis, one- and two-dimensional liquid
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chromatography, and proteomic microarrays in com-
bination with mass spectrometry (MS) are currently
the main tools available to mount a search for cancer
protein biomarkers. Proteomic technologies are used
for identiﬁcation of new markers as well as for
studying potential differences in the processing of
already established protein markers. The hypothesis
is that the protein biosynthesis machinery of cancer
cells is signiﬁcantly changed relative to normal cells
in relation to the production, degradation and post-
translational processing of proteins.
When the protein marker is identiﬁed, several differ-
ent methodologies can be applied when validating the
marker in clinical material. The more common meth-
ods include immunohistochemical staining of frozen
or formalin ﬁxed tissue, and tumour tissue protein
extractions followed by immunological methods such
as Enzyme-linked Immunosorbent Assay (ELISA) or
Radio-Immuno Assay (RIA). The latter methods can
also be applied on bodily ﬂuids such as plasma, serum,
urine or saliva.
At present a number of proteins, e.g. ER, PgR,
ERBB2, and c-kit have proved their value in predicting
clinical sensitivity/resistance to targeted cancer ther-
apy. However, no protein measurement is in routine use
for prediction of sensitivity/resistance to conventional
cytotoxic chemotherapy.
Since most types of chemotherapy induces cell
death by activating the apoptosis machinery in the
cancer cells, many attempts have been made to relate
amount of anti-apoptotic proteins in the cancer cells
to degree of sensitivity/resistance to chemotherapy. We
have chosen to report on one of these proteins, Tissue
Inhibitor of Metalloproteinases type 1 (TIMP-1), since
this protein has recently been shown to be involved
in cellular protection against apoptosis and thereby
resistance to chemotherapy [47]. The TIMP1 gene is
located on chromosome Xp11.23−11.4 and codes for
a soluble 28.5 kDa glycoprotein that consists of 184
amino acids in the mature form. The TIMP-1 protein
can be present as a precursor form, as an unbound
protein (free TIMP-1) or as a 1:1 stoichiometric
complex with proMMP-9 or any of the non membrane-
bound active matrix metalloproteinases (MMPs), in
the latter case inhibiting the proteolytic activity of the
enzymes (for review see Wu¨rtz and colleagues [48]).
TIMP-1’s inhibition of tissue remodelling processes,
such as inﬂammation, wound healing, and cancer
invasion, has mainly been ascribed to its inhibition
of MMP mediated proteolytic activity. In contrast, the
anti-apoptotic function of TIMP-1 has been shown to
be MMP-independent. The MMP independent anti-
apoptotic pathway was ﬁrst demonstrated in a study
of Burkitt’s lymphoma cell lines [49,50]. In this study,
a positive correlation between TIMP-1 expression and
resistance to apoptosis was shown. Addition of re-
combinant TIMP-1 resulted in inhibition of apoptosis,
and addition of anti-TIMP-1 antibodies to neutralise
secreted TIMP-1 resulted in a four-fold increase
in induction of apoptosis. Of speciﬁc interest was
that reduced or alkylated TIMP-1, completely devoid
of all MMP inhibitory activity, effectively inhibited
apoptosis in Burkitt’s lymphoma cells [49,50].
Recently, TIMP-1 was shown to interact with CD63
in MCF10A cells [51]. CD63 is a member of the
tetraspanin family. Of particular interest was that
interaction of TIMP-1 with CD63 inhibited caspase
mediated apoptosis. Binding of TIMP-1 to the cell
surface initiates a signal transduction cascade through
Ras. Ras increases phosphorylation of ERK, and
activates the Raf-1/tyrosine kinase/mitogen-activated
protein kinase (MAPK) and the phosphoinositide
3-kinase (PI3K) signal pathways leading to stimulation
of Cyclin D1 expression. By constitutive activation
of focal adhesion kinase (FAK) and/or through the
PI3 kinase, which phosphorylates Akt and Bad,
TIMP-1 increases the expression of the anti-apoptotic
protein Bcl-XL and thereby preventing activation of
the caspase cascade [52]. Fig. 7 shows part of the
intracellular signalling induced by TIMP-1 binding to
CD63.
In cell culture based systems, lack of cancer cell
TIMP-1 expression results in increased sensitivity
towards chemotherapy [47], suggesting a potential use
of TIMP-1 tumour tissue measurements in predicting
sensitivity/resistance to chemotherapy in clinical can-
cer. Indeed, we have recently published that women
with metastatic breast cancer and high tumour tissue
TIMP-1 and apoptosis
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Fig. 7. Schematic presentation of part of the intracellular signalling
initiated by TIMP-1 binding to CD63.
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TIMP-1 values hardly show any objective response to
antracycline based chemotherapy (0%) while patients
with low TIMP-1 levels had an objective response rate
of 45% [53].
Similarly, in a study including patients with meta-
static colorectal cancer who received 5FU, leucov-
orin and irinotecan, high plasma TIMP-1 levels (di-
chotomised by the median plasma TIMP-1 value) were
indicative of low probability of objective response
to chemotherapy [54]. This decreased probability of
obtaining an objective response to chemotherapy in
plasma high TIMP-1 patients was reﬂected in a
signiﬁcantly decreased time to progression and overall
survival of the patients with 62% of TIMP-1 low
patients being alive at 24 months following treatment
compared with only 7% of patients with high plasma
TIMP-1 levels being alive at this time point. The
Gastrointestinal Cancer Group and the PathoBiology
Group of the European Organisation for Research and
Treatment of Cancer are now in the process of initiat-
ing a prospective study validating these ﬁndings.
A recent publication [55] describes the association
between plasma TIMP-1 levels and response to
endocrine therapy in breast cancer. In a cohort of
251 patients with metastatic breast cancer treated with
second line endocrine therapy, the objective response
rate (CR+PR+SD) was 42% in patients with low
TIMP-1 levels while the objective response rate in
TIMP-1 high patients was only 16%. This difference
was also reﬂected in a signiﬁcant longer time to
progression and a signiﬁcant longer survival of plasma
TIMP-1 low patients.
Using a gel-based method for a mass spectro-
metric site-speciﬁc glycoanalysis, we have recently
characterised the glycosylation pattern of TIMP-1 in
healthy plasma and platelets [56]. The glycoproﬁling
was performed using matrix-assisted laser desorp-
tion/ionisation MS and MS/MS. A total number of 38
glycopeptides were characterised. The glycans were
of the complex type mainly comprising biantennary
structures and few of the characterised glycans con-
tained sialic acids. We are currently analysing TIMP-1
from plasma from cancer patients for potential glyco-
variants. We have also identiﬁed a TIMP-1 splice vari-
ant lacking exon 2 [57]. This splice variant was asso-
ciated with patient prognosis in a group of 1301 breast
cancer patients [58]; however, we still do not have data
on a potential predictive value of this splice variant.
Cell based biomarkers
Major advances have been made recently using molec-
ular biology techniques in the ﬁeld of cancer biomark-
ers and their applications for therapeutic decision mak-
ing by practicing oncologists. This progress resulted
in better understanding of tumour development and
behaviour, thereby providing an increasingly growing
and diversiﬁed array of targeted assays based on
highly integrated genomics and proteomics platforms.
However, our understanding of how multiple genes
and biochemical pathways interact in and between
cancer cells is currently limited. Furthermore, despite
the tremendous progress in the ﬁeld, many impor-
tant mechanisms involved in cancer progression and
metastasis remain poorly understood or even unknown.
These factors are the major reasons why so much
emphasis is now being placed on functional assays
that involve living malignant cells analysed ex vivo
to assess therapeutic efﬁcacy of anti-cancer therapies.
In contrast to targeted assays performed on dead cells
(e.g. immunohistochemistry and FISH) or extracted
cell components (DNA, RNA, protein), functional
assays integrate various components from individual
cellular events, including tumour related pathways and
mediators that are yet unknown and therefore cannot
be evaluated through target speciﬁc testing. However,
the one disadvantage of these assays is the need for
live tumour cells, which in the case of metastatic
disease could represent a limiting step. The underlying
principles of ex vivo drug response testing were
derived from in vitro assays for evaluating the activity
of antibacterial agents pioneered by Robert Koch and
Louis Pasteur in the late 19th century. In 1953, Black
and Spear described the ﬁrst modern ex vivo human
tumour assay in which an attempt was made to predict
clinical response to aminopterin in vivo on the basis
of its cytotoxic activity in vitro [59]. This approach
was further developed by Salmon’s [60] and Von
Hoff’s [61] groups in the 1970–1980s. The next steps
towards optimising this approach were to use a two-
layer agar system to exclude non-malignant cells from
the analysis and to utilise 3H-thymidine incorporation
in tumour cell DNA as an assay endpoint [62]. The
resulting test, referred to as the EDR assay will be
discussed in this review as an example of a rationally
designed ex vivo functional assay that can be used to
predict high likelihood of chemotherapy resistance in
various tumour types.
The EDR Assay is an in vitro drug resistance
test that identiﬁes with >99% accuracy patients that
will not respond to a cancer therapeutic drug or
drug regime [62]. This assay can thus be used to
exclude agents that are unlikely to be clinically
effective, thereby resulting in decreased side effects,
improved response rates and prolonged survival of
cancer patients [63−67]. The EDR assay utilises living
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Fig. 8. The EDR assay technique.
disaggregated tumour cells obtained from a cancer
biopsy and exposes them in culture to chemother-
apeutic agents at suprapharmacologic concentrations
using a tritiated thymidine endpoint (Fig. 8). Tritiated
thymidine passes through the cell membrane and
is converted in a stepwise manner to 3H-dTMP by
thymidylate kinase and nucleoside diphosphate kinase.
The tritiated dTMP is then incorporated into DNA
during the S-phase of the cell cycle. Tumour cells
affected by the anticancer drugs do not divide, or
divide more slowly, and therefore incorporate less of
the radioactive thymidine. By contrast, cells that are
resistant to the drug continually divide and incorporate
radioactive thymidine at a higher level.
It is important to emphasise that in the EDR
assay biopsy derived living cells are cultured in
0.3% semi-liquid agarose on the top of the solid 1%
agar underlayer, thus allowing only tumour cells to
proliferate and excluding normal, non-malignant cells
from the analysis.
By measuring the amount of radioactivity in a sam-
ple, the EDR assay determines the relative resistance
of an individual patient’s cancer cells to a number of
different anti-cancer therapies. An algorithm, based on
Bayesian statistics, is then applied to determine the
probability that a patient will respond to various ther-
apies. It incorporates the percent of growth inhibition
(PCI) caused by a particular drug and classiﬁes the
patients as having extreme drug resistance (EDR) if
the PCI is greater than the median plus one standard
deviation, or intermediate drug resistance (IDR) –
between one standard deviation and the median, or
low drug resistance (LDR) less than the population
median. This algorithm is based on the median
percent inhibition for a given chemotherapeutic agent
across a population of tumour specimens (currently,
>125,000 cases in the Oncotech database (personal
communication)).
The EDR Assay is highly accurate at predicting
clinically inactive drugs and patients whose cancer
cells have Extreme Drug Resistance, with <1%
response rate to the given agent [62]. Patients with
Intermediate Drug Resistance have a ﬁnite, but less
than average, likelihood of responding to a drug. No
deﬁnitive conclusions can be drawn for therapeutic
advantage in the activity of agents to which a tumour
has Low Drug Resistance [68]. Fig. 9, which is
derived from the initial clinical study validating the
EDR assay [62], shows 450 double-blinded corre-
lations between clinical response to chemotherapy
(non-responders versus responders) plotted against
individual data generated in the EDR assay (expressed
as PCI). While 52% (115 out of 222) cases in the
LDR group responded to chemotherapy, only 0.8% (1
out of 127) of patients in the EDR category achieved
detectable clinical responses.
Drug exposures in the EDR assay are greater than
those achievable pharmacologically. The period of
drug exposure is signiﬁcantly longer (days in the EDR
Assay, as compared to hours in the patient) and at
concentrations which continuously approximate the
peak plasma level. As an example, for Paclitaxel,
this would translate to an 8.1-fold greater exposure
in the EDR assay than what is routinely achieved
at standard doses in the patient. When tumour cells
continue to proliferate in the presence of drug at such
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Fig. 9. EDR assay validation.
Fig. 10. Overall (A) and progression-free survival (B) in platinum-sensitive ovarian cancer
levels, it is unlikely that the tumour will respond
to the signiﬁcantly lower exposures achieved in the
patient [62,67,69].
The EDR assay can also be used to evaluate the
activity of novel chemical entities being developed
as anti-cancer drugs. New compounds can be tested
in the EDR assay in the surrogate testing mode, to
approximate a clinical EDR assay. After applying
the algorithm to the tumours tested, one can stratify
sensitive and resistant phenotypes within a single type
of tumour or between tumour types. The sensitive
and resistant tumours can then be compared through
molecular or cellular analyses to identify biomarkers
that are predictive of response. In addition, the EDR
assay can detect tumour types, which are innately
resistant to the compound. This information can be
subsequently used to choose tumour types or a subset
of tumours in which the compound will be more
active in the patient, and, thus, be more likely to get
regulatory approval.
Several studies performed by Oncotech and inde-
pendent research groups in ovarian, breast, and brain
cancer, as well as some recent studies in other tumour
types (colorectal, lung, and endometrial cancers;
melanoma) indicate that lack of in vitro cytotoxic
activity of several chemotherapeutic agents measured
in the EDR assay is associated with poor patient
outcomes [64,70,71]. In a prospective EDR assay-
guided study on 100 patients with recurrent ovarian
cancer, clinical response to platinum based regimens
was compared in 50 women whose chemotherapy
was based on the results of the EDR assay versus
clinical response in 50 control cases treated empir-
ically [72]. This study demonstrated that platinum-
sensitive patients in the EDR assay-guided group
exhibited higher overall response rate than those in
the control group (65% versus 35%, respectively;
P = 0.02). Furthermore, as shown in Fig.10, platinum-
sensitive patients in the EDR-treated cohort had longer
overall and progression-free survival rates (38 and 15
months, respectively) than control, empirically-treated
patients (21 and 7 months, respectively; P = 0.005 for
overall and P = 0.0002 for progression-free survival).
However, despite the proven value of the EDR assay
in predicting disease-speciﬁc survival and clinical
resistance to chemotherapy in solid tumours (mostly,
in ovarian cancer), the ability of the EDR assay to
optimise speciﬁc clinical outcomes through assay-
guided treatment decisions remains to be established
in other tumour types. Supplementary data, especially
from appropriately controlled prospective studies are
needed to conclusively prove the value of the EDR
assay in guiding chemotherapy in solid tumours and
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its ability to improve objective clinical outcomes for
cancer patients.
Clinical validation of predictive markers
In order to have clinical impact, a new predictive
marker has to pass a number of analytical and clinical
validation steps [73].
A major dilemma associated with assays for
biomarkers is that various assays may employ dif-
ferent reagents (e.g. antibodies), which may gen-
erate non-equivalent test results. Also, variations
in reagent preparations, sample processing and the
use of different standards may result in discordant
test results. Therefore, reagents, assays and proce-
dures should be standardised and the quality of
biomarker assay results should be monitored by
continuous between-laboratory proﬁciency testing of
performance. Biomarkers are often used in the clinical
setting to provide additional information that will
inﬂuence clinical decision making, while only few
guidelines have been established to inform about how
a biomarker should become standard for a certain
type of cancer. Hayes and colleagues, 1996 [74]
therefore proposed that it is highly necessary to
establish standard criteria for evaluation of biomarkers
and to standardise the biomarker information for
clinical utility. To judge whether these factors have
added value over the traditional factors, McGuire
and colleagues, 1992 [75] proposed guidelines for
evaluating new cancer biomarkers, including a bio-
logic hypothesis for the new factor, adequate sample
size, risk of sampling bias, appropriate test system,
establishment of cut-off values in a training data-set
and conﬁrmation of the observation in a validation
data set. Biomarker assay results are often quite
heterogeneous, depending on the composition of the
specimen, way of tissue processing, and design and
speciﬁcity of an assay and, as important, statistical
methods used for evaluation of data. It is of utmost
importance to note that uniform handling applies to
all of the laboratory steps including use of highly
standardised and optimised reagents, tissue collection,
storage and processing, the analytical procedures,
and subsequent data processing. Within Europe, a
multitude of translational multi-centre cancer studies
have been co-ordinated by the EORTC. Within this
consortium the PathoBiology Group was established
to research and advise on common, or equivalent,
methodologies for biomarker assays and to ensure
that appropriate External Quality Assessment (EQA)
schemes are applied. As an example, for the past
25 years for ER and PgR, large-scale EQA trials,
amounting to participating 165 institutions/hospitals
from 18 countries, have been carried out and organised
by the PathoBiology Group [76,77].
When a validated assay is available the clinical
studies can be initiated. It is recommended to start
analysing material collected from prior well-controlled
clinical studies, from which high quality sample ma-
terial, as well as clinical outcome regarding treatment
efﬁcacy, is available. Following these retrospective
studies, the prospective clinical studies can be started.
We recommend that the ﬁrst study is designed as
an adjunct to a clinical study in which the primary
objective is to test the efﬁcacy of one or more drugs. In
such a study, sample collection should be prospective
and strictly follow predeﬁned conditions (Standard
Operating Procedures) regarding sample collection,
storage handling, analyses and data reporting. The
next step in the validation is a well-dimensioned
prospective study where the primary objective is to
validate the predictive power of the marker in question.
A simple trial design is as follows: Patients are
randomised to receive either standard treatment or
marker-guided treatment. End-points will be objective
response rate (RECIST criteria), or time to progression
and less frequent overall survival. These types of
clinical studies can only be performed in cancer types
for which more than one treatment option exists and
are especially helpful if the efﬁcacy of the different
treatments is considered equal.
For example, in the majority of patients with
metastatic colorectal cancer (mCRC), chemotherapy
is the treatment of choice. Survival following chemo-
therapy of mCRC has improved substantially over
recent years. Whereas survival without chemotherapy
was limited to 8.5 months, the ﬁrst effective drug
(5-ﬂuorouracil, 5FU) was shown to increase the
median overall survival to 12 months [78]. Addition
to 5FU of either irinotecan or oxaliplatin increased
the efﬁcacy: If one of these drugs is added to
5FU, the response rates rise from approximately 20%
to approximately 50% with either the combination
irinotecan/5FU (FOLFIRI) [79−81] or oxaliplatin/5FU
(FOLFOX) [82−84]. Irinotecan and oxaliplatin based
chemotherapy differs in toxicity proﬁle (diarrhoea
and alopecia versus neurotoxicity), but there is no
meaningful difference with regard to the overall
efﬁcacy. Because efﬁcacy and overall toxicity are
similar in the whole patient population, both regimens
are equally used in ﬁrst line therapy.
One unresolved problem with either of the chemo-
therapy combinations is that up to 25% of patients
have tumours that are inherently resistant to the chosen
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chemotherapy schedule (FOLFOX or FOLFIRI) [81,
82,85]. The current clinical approach selects one
treatment regimen over another based on predicted
success (and to a lesser degree also toxicity) in
large patient cohorts. Using this approach, there is,
necessarily, a large fraction of individual patients who
have no beneﬁt whatsoever and may even suffer from
the chemotherapy. These patients are unnecessarily
exposed to treatment toxicity, and they experience dis-
ease progression, which affects the performance status
and the capability to tolerate further chemotherapy. In
contrast, they might rather proﬁt from an alternative
regimen.
In contrast to predict chemotherapy response, it is
at present more important to predict chemotherapy
resistant metastatic colorectal cancer. If chemotherapy
resistance to one type of cytotoxic drug could be
predicted for individual patients, these patients could
already, as 1st line treatment, receive the other treat-
ment combination and thereby increase their chance
of treatment beneﬁt. In addition, such an approach
would avoid the costs for approximately 2 months
of ineffective treatment (with weekly costs of up to
€500), and thereby be highly cost-effective. With the
currently available evidence, there is no way to predict
response or resistance to the given chemotherapeutic
treatment in the individual patient, let alone any
guidance to select one regimen instead of another
one.
Thus, there is a need for research focusing on
the identiﬁcation and development, including clinical
implementation, of predictive markers for each ex-
isting chemotherapeutic drug in addition to general
markers for chemotherapy sensitivity/resistance. Also,
a clear discrimination between diagnostic, prognostic
and predictive markers is needed, including statistical
methods that can facilitate this separation.
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